Oxiracetam: what does this study show?
40 outpatients randomized in a double-blind trial to oxiracetam 800 mg twice daily or placebo for 90 days. Route is not specified in the abstract.
Several cognitive tests and instrumental daily-living measures favored oxiracetam. No side effects were observed in this trial.
A 40-person trial cannot establish uncommon or long-term risks. Dementia findings do not establish healthy-person enhancement; L-oxiracetam studies concern a specific stereoisomer.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
A 40-person trial cannot establish uncommon or long-term risks. Dementia findings do not establish healthy-person enhancement; L-oxiracetam studies concern a specific stereoisomer.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.